<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097730</url>
  </required_header>
  <id_info>
    <org_study_id>18-26045</org_study_id>
    <secondary_id>UG1EY028518</secondary_id>
    <nct_id>NCT04097730</nct_id>
  </id_info>
  <brief_title>Steroids and Cross-linking for Ulcer Treatment</brief_title>
  <acronym>SCUT II</acronym>
  <official_title>Steroids and Cross-linking for Ulcer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas M. Lietman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aravind Eye Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Steroids and Cross-linking for Ulcer Treatment (SCUT II) is an international, randomized,
      double-masked, clinical trial. The purpose of this study is to determine differences in
      6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial
      treatment plus collagen cross-linking (CXL), as well as to further evaluate findings from
      subgroup analyses of SCUT. Patients presenting to the Aravind Eye Care System (India), Kaiser
      Permanente Northern California (USA), or the University of California, San Francisco (USA)
      with smear-positive and/or culture-positive typical (i.e. non-Nocardia or Mycobacteria)
      bacterial corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity
      of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be
      randomized to one of three treatment groups:

      Group 1: Standard therapy, topical 0.5% moxifloxacin plus topical placebo plus sham CXL Group
      2: Early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05% plus sham CXL
      Group 3: CXL plus early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05%
      plus CXL
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>6 Months</time_frame>
    <description>Best Spectacle-Corrected Visual Acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>3 Weeks, 3 Months, 12 Months</time_frame>
    <description>Best Spectacle-Corrected Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ulcers Testing Positive for Bacteria on Repeat Culture</measure>
    <time_frame>2 Days</time_frame>
    <description>Microbiological cure on repeat culture: A scraping of the corneal ulcer taken at 48 hours, then swabbed onto a culture plate and assessed for bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Size</measure>
    <time_frame>3 Weeks, 3 Months, 6 Months 12 Months</time_frame>
    <description>Geometric Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Depth</measure>
    <time_frame>3 Weeks, 3 Months, 6 Months, 12 Months</time_frame>
    <description>Geometric Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Keratitis Bacterial</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Ophthalmic</intervention_name>
    <description>Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.</description>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_label>Early Steroids</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluprednate Ophthalmic</intervention_name>
    <description>Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.</description>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_label>Early Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin Ophthalmic</intervention_name>
    <description>All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.</description>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
    <other_name>Corneal Cross-Linking with Riboflavin Ophthalmic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Placebo</intervention_name>
    <description>Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Corneal ulcer that is smear positive and/or culture positive (within 24 hours) for
             typical bacteria (i.e. non-Nocardia or Mycobacteria)

          -  Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) or
             worse

          -  Corneal thickness ≥300 µm, as measured on AS-OCT

          -  Age over 18 years

          -  Basic understanding of the study as determined by the physician

          -  Commitment to return for follow up visits

        Exclusion Criteria:

          -  Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e.
             herpes, both bacteria and acanthameoba on gram stain)

          -  Impending or frank perforation at recruitment

          -  Involvement of sclera at presentation

          -  Non-infectious or autoimmune keratitis

          -  History of corneal transplantation or recent intraocular surgery

          -  Pinhole visual acuity worse than 20/200 in the unaffected eye

          -  Participants who are decisionally and/or cognitively impaired
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ariana Austin, MS</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Lietman, MD</last_name>
    <phone>415-502-2662</phone>
    <email>tom.lietman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariana Austin, MS</last_name>
    <phone>415-502-0275</phone>
    <email>ariana.austin@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
      <phone>650-299-2111</phone>
      <email>jennifer.rose-nussbaumer@kp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Francis I. Proctor Foundaiton</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tom Lietman, MD</last_name>
      <phone>415-502-2662</phone>
      <email>tom.lietman@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ariana Austin, MS</last_name>
      <phone>415-502-0275</phone>
      <email>ariana.austin@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Care System</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>N.V. Prajna</last_name>
      <email>prajna@aravind.org</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Difluprednate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

